MA30901B1 - Therapie de combinaison sequentielle - Google Patents

Therapie de combinaison sequentielle

Info

Publication number
MA30901B1
MA30901B1 MA31888A MA31888A MA30901B1 MA 30901 B1 MA30901 B1 MA 30901B1 MA 31888 A MA31888 A MA 31888A MA 31888 A MA31888 A MA 31888A MA 30901 B1 MA30901 B1 MA 30901B1
Authority
MA
Morocco
Prior art keywords
combination therapy
sequential combination
angiogenesis
disorders
ectodomatic
Prior art date
Application number
MA31888A
Other languages
English (en)
Inventor
Rakesh K Jain
Clive R Wood
Daniel T Dransfield
Antonio Arulanandam
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of MA30901B1 publication Critical patent/MA30901B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX PROCÉDÉS DESTINÉS AU TRAITEMENT DE TROUBLES LIÉS À L'ANGIOGENÈSE. LESDITS TROUBLES LIÉS À L'ANGIOGENÈSE SONT TRAITÉS PAR L'ADMINISTRATION D'UN AGENT DE LIAISON ECTODOMAINE TIE1 ET D'UN AGENT ANTAGONISTE VEGF.
MA31888A 2006-10-17 2009-05-14 Therapie de combinaison sequentielle MA30901B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85226306P 2006-10-17 2006-10-17
US87573606P 2006-12-19 2006-12-19

Publications (1)

Publication Number Publication Date
MA30901B1 true MA30901B1 (fr) 2009-11-02

Family

ID=39314809

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31888A MA30901B1 (fr) 2006-10-17 2009-05-14 Therapie de combinaison sequentielle

Country Status (17)

Country Link
US (1) US20080160019A1 (fr)
EP (1) EP2073826A4 (fr)
JP (1) JP2010506951A (fr)
KR (1) KR20090067214A (fr)
AU (1) AU2007311092A1 (fr)
BR (1) BRPI0717760A2 (fr)
CA (1) CA2666714A1 (fr)
CR (1) CR10798A (fr)
EA (1) EA200900562A1 (fr)
EC (1) ECSP099336A (fr)
IL (1) IL198026A0 (fr)
MA (1) MA30901B1 (fr)
MX (1) MX2009004070A (fr)
NI (1) NI200900057A (fr)
NO (1) NO20091375L (fr)
TN (1) TN2009000136A1 (fr)
WO (1) WO2008048996A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
US20080260861A1 (en) * 2004-04-07 2008-10-23 The General Hospital Corporation Modulating Lymphatic Function
WO2008089070A2 (fr) * 2007-01-12 2008-07-24 Dyax Corp. Polythérapie pour le traitement du cancer
EP2156834A1 (fr) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Compositions pharmaceutiques ophtalmiques comprenant du Sorafenib pour le traitement de pathologies néoangiogéniques de l'ýil
CA2794631A1 (fr) * 2010-03-31 2011-10-06 Universite De Geneve Preparations d'anticorps stabilises et utilisations correspondantes
US9804675B2 (en) 2013-06-27 2017-10-31 Elwha Llc Tactile feedback generated by non-linear interaction of surface acoustic waves
US20150003204A1 (en) * 2013-06-27 2015-01-01 Elwha Llc Tactile feedback in a two or three dimensional airspace
KR20250051157A (ko) 2019-06-05 2025-04-16 리제너론 파아마슈티컬스, 인크. 정밀 투여량 전달을 위한 디바이스 및 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2223705T3 (es) * 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US20040132675A1 (en) * 2002-02-08 2004-07-08 Calvin Kuo Method for treating cancer and increasing hematocrit levels
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
JP2007528720A (ja) * 2003-08-12 2007-10-18 ダイアックス コーポレイション Ｔｉｅ１結合リガンド
JP2008532476A (ja) * 2004-08-12 2008-08-21 ダイアックス コーポレーション 複合結合タンパク質
WO2008089070A2 (fr) * 2007-01-12 2008-07-24 Dyax Corp. Polythérapie pour le traitement du cancer

Also Published As

Publication number Publication date
NI200900057A (es) 2010-02-02
CA2666714A1 (fr) 2008-04-24
CR10798A (es) 2009-06-09
MX2009004070A (es) 2009-04-27
ECSP099336A (es) 2009-06-30
US20080160019A1 (en) 2008-07-03
IL198026A0 (en) 2011-08-01
JP2010506951A (ja) 2010-03-04
WO2008048996A2 (fr) 2008-04-24
AU2007311092A1 (en) 2008-04-24
KR20090067214A (ko) 2009-06-24
WO2008048996A9 (fr) 2008-09-12
EA200900562A1 (ru) 2009-10-30
WO2008048996A3 (fr) 2008-07-03
BRPI0717760A2 (pt) 2013-11-12
TN2009000136A1 (en) 2010-10-18
EP2073826A4 (fr) 2010-12-15
EP2073826A2 (fr) 2009-07-01
NO20091375L (no) 2009-07-10

Similar Documents

Publication Publication Date Title
MA30901B1 (fr) Therapie de combinaison sequentielle
NZ617083A (en) Combination therapy for the treatment of ocular neovascular disorders
EP1551369A4 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
MA29326B1 (fr) Combinaison de composes organiques
EP1838320A4 (fr) Antagonistes de cxcr4 pour le traitement de troubles medicaux
EA201100544A1 (ru) Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
EP1755654A4 (fr) Methodes et systemes de traitement d'affections neurologiques du systeme nerveux central
WO2007087457A3 (fr) Polytherapie destinee au traitement de troubles neovasculaires
GEP20115195B (en) Antibodies directed against amyloid-beta peptide and use thereof
WO2005107726A3 (fr) Procede pour le traitement de mal de dos
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
MA31941B1 (fr) Bis-pyridylpyridones en tant qu'antagonistes du récepteur 1 de l'hormone de concentration de la mélanine
NZ597648A (en) Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
NO20062300L (no) Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser
MX2007006066A (es) Inhibidores de jnk para el tratamiento de lesiones del snc.
EP1738761A4 (fr) Médicament préventif et/ou remède pour des affections abdominales inflammatoires
SG148186A1 (en) Methods and reagents for the treatment of inflammatory disorders
EA200501620A1 (ru) Лечение состояний, включающих амилоидные бляшки
EP1646381A4 (fr) Therapie combinee pour le traitement des maladies inflammatoires chroniques
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
IL185653A0 (en) Pharmaceutical compositions containing an antibody which binds the stalk region of kim-1
WO2007011873A3 (fr) Procede permettant de traiter des maladies neovasculaires intraoculaires
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target